PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome

Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer

(2016) Christophe Massard et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

(2016) Weiping Zou et al.   Science Translational Medicine

Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition

(2016) Claire F. Friedman et al.   Current Oncology Reports

Clinical utility of nivolumab in the treatment of advanced melanoma

(2016) Richard D. Carvajal et al.   Therapeutics and Clinical Risk Management

EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB

(2015) Kailong Lin et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth

(2015) Sonja Kleffel et al.   CELL

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma

(2015) Kathleen M. Mahoney et al.   CLINICAL THERAPEUTICS

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

(2015) Jeffrey S Weber et al.   LANCET ONCOLOGY

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti–PD-1 Therapy in Melanoma

(2015) Blanca Homet Moreno et al.   SEMINARS IN ONCOLOGY

Antagonists of PD-1 and PD-L1 in Cancer Treatment

(2015) Evan J. Lipson et al.   SEMINARS IN ONCOLOGY

Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer

(2015) Michael T. Barrett et al.   Oncotarget

Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation

(2015) E. M. Van Allen et al.   Cancer Immunology Research

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

(2014) Suzanne L. Topalian et al.   JOURNAL OF CLINICAL ONCOLOGY

RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance

(2014) Yanping Xiao et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Fusion Protein of Mutant B7-DC and Fc Enhances the Antitumor Immune Effect of GM-CSF-secreting Whole-cell Vaccine

(2014) Masatsugu Kojima et al.   JOURNAL OF IMMUNOTHERAPY

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials

(2014) Jason Madore et al.   Pigment Cell & Melanoma Research

A melanoma helper peptide vaccine increases Th1 cytokine production by leukocytes in peripheral blood and immunized lymph nodes

(2014) Patrick M Dillon et al.   Journal for ImmunoTherapy of Cancer

Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer

(2013) M. Sznol et al.   CLINICAL CANCER RESEARCH

Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy

(2013) Omid Hamid et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Peptide Vaccination in Montanide Adjuvant Induces and GM-CSF Increases CXCR3 and Cutaneous Lymphocyte Antigen Expression by Tumor Antigen-Specific CD8 T Cells

(2013) E. Clancy-Thompson et al.   Cancer Immunology Research

Immunotype and Immunohistologic Characteristics of Tumor-Infiltrating Immune Cells Are Associated with Clinical Outcome in Metastatic Melanoma

(2012) G. Erdag et al.   CANCER RESEARCH

B7-DC-Ig Enhances Vaccine Effect by a Novel Mechanism Dependent on PD-1 Expression Level on T Cell Subsets

(2012) M. Mkrtichyan et al.   JOURNAL OF IMMUNOLOGY

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

(2012) J. M. Taube et al.   Science Translational Medicine

Aging-associated B7-DC+B cells enhance anti-tumor immunity via Th1 and Th17 induction

(2011) Kei Tomihara et al.   AGING CELL

Essential Role of PDL1 Expression on Nonhematopoietic Donor Cells in Acquired Tolerance to Vascularized Cardiac Allografts

(2011) L. V. Riella et al.   AMERICAN JOURNAL OF TRANSPLANTATION

PD-1 expression on Melan-A-reactive T cells increases during progression to metastatic disease

(2011) Holger Krönig et al.   INTERNATIONAL JOURNAL OF CANCER

Crucial roles of B7-H1 and B7-DC expressed on mesenteric lymph node dendritic cells in the generation of antigen-specific CD4+Foxp3+ regulatory T cells in the establishment of oral tolerance

(2010) T. Fukaya et al.   BLOOD

Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma

(2010) Ryosuke Hino et al.   CANCER

Overall survival and PD-L1 expression in metastasized malignant melanoma

(2010) Jules Gadiot et al.   CANCER

Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T cell functions

(2010) Tony Avril et al.   JOURNAL OF NEUROIMMUNOLOGY

Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+ T-Cell Infiltration and Survival of Patients with Cervical Carcinoma

(2009) R. Karim et al.   CLINICAL CANCER RESEARCH

Adoptive cell therapy for the treatment of patients with metastatic melanoma

(2009) Steven A Rosenberg et al.   CURRENT OPINION IN IMMUNOLOGY

Final Version of 2009 AJCC Melanoma Staging and Classification

(2009) Charles M. Balch et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

(2009) Loise M. Francisco et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Regulation of arginase I activity and expression by both PD-1 and CTLA-4 on the myeloid-derived suppressor cells

(2008) Yu Liu et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer

(2008) Martin Loos et al.   CANCER LETTERS